Sepsis and Hospital Mortality
ConditionSepsis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Calabria
About this trial
Sepsis is one of the leading causes of hospital mortality, with a rate of approximately 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards. Currently, diagnostic criteria such as the Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack sufficient specificity and accuracy. No established parameters are available for early and timely diagnosis. This study aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes previously validated for non-invasive glucose monitoring. The acquired data will be analyzed using the Anritsu VectorStar VNA to identify innovative and reliable parameters associated with the presence of severe infections.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Cardiology patients without documented infection (Control Group)
Patients with sepsis
Patients with nosocomial infection
Disqualifiers
Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure
Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants
Patients with cancer
Patients with diseases involving the immune system (e.g., lymphomas, leukemias)
Trial design
Treatments tested in this trial
- conductivity and dieletric constant
Treatment groups
100 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov